Theranostics Market Insights 2025-2034: Growth Forecast and Strategic Priorities

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Theranostics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market volume of theranostics has experienced a rapid increase in the past years. It is projected to expand from $111.1 billion in 2024 to $123.33 billion in 2025, with a compound annual growth rate (CAGR) of 11.0%. The growth observed during the historic period is due to developments in molecular imaging, the transition to value-based healthcare, and incorporation into oncology.

Theranostics Market Size Forecast: What's the Projected Valuation by 2029?
The market size for theranostics is predicted to witness a swift expansion within the upcoming years, reaching ""$185.73 billion by 2029 with an annual compound growth rate (CAGR) of 10.8%. The anticipated growth during the forecast period is due to an increase in precision medicine initiatives, wider applications that extend beyond oncology, an aging population and chronic illnesses, progress in biomarker discovery, along with government backing and funding. Future trends within this period encompass regulatory support, the emergence of companion diagnostics, a heightened attention towards cancer theranostics, patient involvement and consciousness, as well as technological synthesis.

View the full report here:
https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

What Are the Drivers Transforming the Theranostics Market?
The surge in cancer occurrences is anticipated to boost the theranostics market's expansion in the future. Cancer, defined as unchecked cellular growth that affects diverse organs, contributes significantly to global morbidity and mortality. Theranostics - the amalgamation of therapy and diagnostics - holds potential in managing cancer and chronic diseases. It allows for personalized and precise treatments by marrying diagnostic and therapeutic capacities, creating room for innovation within the healthcare sector. Therefore, the growth in cancer patient numbers will fuel the theranostics market's increase. For example, data from the National Cancer Institute (NCI) - a US government agency under the National Institutes of Health (NIH) dedicated to cancer research, prevention, and treatment - revealed in January 2022 that about 5.4% (or 18.1 million individuals) of the US population are cancer survivors. Additionally, about 623,405 individuals were living with metastatic breast, prostate, lung, colorectal, bladder cancer or metastatic melanoma in 2022, a figure predicted to rise to 693,452 by 2025. Consequently, the increasing cancer prevalence is stimulating growth in the theranostics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

What Long-Term Trends Will Define the Future of the Theranostics Market?
Major theranostics market players are centred towards the creation of technologically innovative solutions like theranostics clinical trials. Such solutions aim for improvement in personalized medicine by combining diagnostic measures and therapeutics in a unified treatment approach, further enhancing patient outcomes. The purpose of theranostics clinical trials is to evaluate the combined usage of diagnostic tests with targeted therapies, enabling the fine-tuning of treatment strategies for each patient. It emphasizes determining the efficacy of distinct treatments in accordance with specific biomarkers of every patient, thus promoting personalized medicine. For instance, the COMBAT Trial was initiated in May 2024 by an American cancer treatment center, BAMF Health, officially known as "A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617" (NCT05633160). The salient features of this trial include an expeditious activation process by BAMF Health's BAMF RapAct program, enabling the trial's initiation in just seven weeks, as well as a focus on novel radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR). The goal here is to develop better treatment alternatives for patients with limited therapeutic options.

Which Segments in the Theranostics Market Offer the Most Profit Potential?
The theranostics market covered in this report is segmented -

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases
2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies
3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:
1) By Neurological Disorders: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Other Neurological Disorders
2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension, Other Cardiovascular Diseases
3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis, Other Immunological Disorders
4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Oncology Diseases
5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders, Other Diseases

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp

Which Firms Dominate the Theranostics Market by Market Share and Revenue in 2025?
Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Which Regions Offer the Highest Growth Potential in the Theranostics Market?
North America was the largest region in the global theranostics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10823

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe - +44 7882 955267
Asia: +91 88972 63534
Americas - +1 310-496-7795
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.